Glucose Concentrations Less Than 54 mg/dL Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

Date: 
December, 2016
December 2016. The American Diabetes Association and the European Association for the Study of Diabetes have released a statement agreeing that glucose levels lower than 54 mg/dL (3.0 mmol/L) should be reported in clinical trials evaluating drugs for the treatment of diabetes. This position statement outlines the groups’ decision-making process and rationale for selecting this threshold and also indicates that hypoglycemia levels of less than 70 mg/dL do not need to be routinely reported in clinical trials.